24
Participants
Start Date
December 20, 2019
Primary Completion Date
June 30, 2027
Study Completion Date
June 30, 2027
Etelcalcetide
Etelcalcetide has been shown to be safe and efficacious in treating adult chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT) by simultaneously controlling intact parathyroid hormone (iPTH), calcium (Ca), and phosphorus and has recently been approved for use in adult patients with secondary hyperparathyroidism (SHPT) treated with hemodialysis in both the United States and Europe
TERMINATED
Semmelweis Egyetem, Budapest
TERMINATED
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Altalanos Orvostudomanyi Kar, Szeged
TERMINATED
Universitair Ziekenhuis Gent, Ghent
RECRUITING
General Children Hospital Panagioti and Aglaias Kyriakou, Athens
RECRUITING
Universitaetsklinikum Hamburg Eppendorf, Hamburg
COMPLETED
Medizinische Hochschule Hannover, Hanover
RECRUITING
Hospital Universitario Virgen del Rocio, Seville
TERMINATED
Azienda Ospedaliera Universitaria Meyer, Florence
RECRUITING
Universitaetsklinikum Koeln, Cologne
COMPLETED
Kindernierenzentrum Bonn, Bonn
RECRUITING
Ippokrateio General Hospital of Thessaloniki, Thessaloniki
RECRUITING
Universitaetsklinikum Heidelberg, Zentrum fuer Kinder und Jugendmedizin, Heidelberg
TERMINATED
Hospices Civils de Lyon Hopital Femme Mere Enfant, Bron
COMPLETED
Hopital Armand Trousseau, Paris
COMPLETED
Fakultni nemocnice v Motole, Prague
TERMINATED
Childrens Hospital, Affiliate of Vilnius University Hospital Santaros Klinikos, Vilinus
TERMINATED
Uniwersytecki Szpital Dzieciecy w Krakowie, Krakow
RECRUITING
Unidade Local de Saude de Santo Antonio, EPE - Hospital de Santo Antonio, Porto
RECRUITING
Hospital Universitari Vall d Hebron, Barcelona
RECRUITING
Royal Hospital for Sick Children, Glasgow
RECRUITING
Leeds Teaching Hospitals NHS Trust, Leeds
TERMINATED
Great Ormond Street Hospital for Children, London
RECRUITING
University Hospital Southampton NHS Foundation Trust, Southampton
Lead Sponsor
Amgen
INDUSTRY